Revenue and Profit - Revenue for Q3 2021 was CNY 139,783,840.34, an increase of 9.20% compared to the same period last year[2] - Net profit attributable to shareholders was CNY -4,172,489.69, a decrease of 113.62% year-on-year[2] - The company reported a basic earnings per share of CNY -0.0358, down 105.11% from the same period last year[2] - Total revenue for the current period was CNY 381,341,501.33, a decrease of approximately 13.5% compared to CNY 441,013,158.38 in the previous period[25] - The company's net profit attributable to shareholders decreased to CNY 430,854,389.14 from CNY 465,458,299.52, a decline of approximately 7.4%[24] - The net profit for Q3 2021 was -4,026,910.21 CNY, compared to a net profit of 101,775,629.99 CNY in the same period last year, indicating a significant decline[26] - Operating profit for Q3 2021 was -3,880,071.58 CNY, a sharp decrease from 103,877,512.59 CNY in Q3 2020[26] - The total comprehensive income attributable to the parent company was -4,110,416.45 CNY, compared to 101,815,589.87 CNY in the same period last year[27] Assets and Liabilities - Total assets at the end of Q3 2021 reached CNY 1,821,346,947.47, representing a 56.38% increase from the end of the previous year[3] - The company's total liabilities increased to CNY 408,642,364.75 from CNY 313,672,792.10, reflecting a growth of about 30.3%[23] - The company's registered capital increased from CNY 5,835 million to CNY 11,670 million following the approval of a capital change at the shareholders' meeting[19] - The company’s long-term borrowings increased to CNY 204,140,359.42 from CNY 133,004,653.53, reflecting a growth of about 53.5%[23] Cash Flow - Cash flow from operating activities showed a net amount of CNY 2,267,161.54, a significant decrease of 98.27% year-to-date[2] - Operating cash flow decreased by 98.27% to ¥2,267,161.54 compared to ¥130,889,358.12 in the same period last year, primarily due to rising raw material costs and declining sales prices[11] - Cash flow from operating activities generated a net cash inflow of 2,267,161.54 CNY, down from 437,167,664.87 CNY in the previous year[31] - Investment activities resulted in a net cash outflow of -112,278,356.50 CNY, compared to -125,883,969.31 CNY in the previous year[31] - Financing activities generated a net cash inflow of 657,598,389.29 CNY, a significant increase from -30,034,742.55 CNY in Q3 2020[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,175[13] - The largest shareholder, Yu Yangchao, holds 30.84% of the shares, amounting to 35,987,628 shares[14] - The second-largest shareholder, Ruan Xiulian, holds 8.30% of the shares, totaling 9,683,876 shares[14] - The company has a total of 43,760,000 restricted shares, which will be released on April 11, 2024[18] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest holding being 35,987,628 shares[14] - The company is actively managing its shareholder structure, with several shareholders having significant stakes and potential future liquidity events[17] - The company has seen an increase in the number of shares held by institutional investors, indicating growing interest from the investment community[15] Expenses and Costs - Sales expenses rose to CNY 5,418,513.11, a 74.75% increase due to enhanced sales efforts and increased personnel[10] - Financial expenses turned negative at CNY -9,438,143.94, a decrease of 645.35% attributed to increased interest income[10] - The total operating costs rose to CNY 396,225,132.55, up from CNY 344,835,842.14, indicating an increase of about 15%[25] - The company incurred a total operating expense of 385,151,310.83 CNY, compared to 306,278,306.75 CNY in the same quarter last year[31] Government Support and Future Plans - The company received government subsidies amounting to CNY 10,417,491.92, a 49.53% increase compared to the previous year[10] - The company plans to continue focusing on market expansion and product development to enhance future performance[18] - The company established new subsidiaries in Chongqing and Wangdu County, enhancing its market presence[19] Inventory and Cash Equivalents - The company reported a significant increase in inventory, which rose to CNY 107,274,054.43 from CNY 83,823,317.74, an increase of approximately 28%[21] - The company's cash and cash equivalents significantly increased to CNY 739,584,919.14 from CNY 191,997,724.81, marking a growth of about 285.5%[21] - The company reported a cash and cash equivalents balance of 739,584,919.14 CNY at the end of the quarter, up from 85,003,138.97 CNY at the end of the same quarter last year[32]
华绿生物(300970) - 2021 Q3 - 季度财报